arrow
P

Pascale Flandrin-Gresta

institut bergonie
H指数:18
被引数:1,072

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi-LMC study

克隆和基因组决定因素在e1a2 BCR::ABL1慢性髓性白血病中的作用:一项Fi-LMC研究

2026-08-040
OAAI
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry

初治AML患者接受阿扎胞苷和维奈克拉治疗时可测量残留疾病对预后的影响:法国VENAURA登记研究的结果

Leukemia
IF13.4
2026-07-170
OAAI
Myeloid neoplasms risks for germline DDX41 pathogenic variants carriers

携带胚系DDX41致病性变异的髓系肿瘤风险

2025-10-030
PRE
Development and validation of the FIP-Score for the screening of FIP1L1::PDGFRA-associated hypereosinophilic syndrome

FIP-Score的开发与验证:用于FIP1L1::PDGFRA相关嗜酸性粒细胞增多综合征的筛查

2025-09-220
PRE
Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study

Venetoclax和azacitidine用于NPM1或CBF AML在密集化疗后的分子复发:一项FILO研究

2025-08-210
OAAI
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?

长期B细胞淋巴瘤应答者接受CD19定向CAR T细胞治疗后出现的髓系肿瘤,风险是否随时间推移而增加?

LEUKEMIA
IF13.4
2025-04-240
OA
Implementation science in hemato-oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)

法国通过恶性血液病分子生物学小组(Groupe des Biologistes Moléculaire des Hémopathies Malignes, GBMHM)在血液肿瘤分子诊断领域的转化研究。

2025-04-080
OAAI
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study
LEUKEMIA
IF13.4
2024-07-171
OAAI
Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia

FLT3基因中的非常短的插入在急性髓性白血病中具有治疗意义

2023-12-151
OAAI
Epidemiology, clinical picture and long-term outcomes ofFIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients
2020-09-1943
OAAI
Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia
2016-08-1898
OAAI